Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.66 SEK | -3.57% | +16.35% | +89.54% |
May. 31 | Hansa Biopharma Finalizes Patient Randomization for Use of Imlifidase inKidney Transplantation Trial | MT |
May. 31 | Hansa Biopharma Completes Randomization in Pivotal Phase 3 Us Confides Trial | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+89.54% | 301M | |
+58.54% | 59.34B | |
+43.17% | 40.24B | |
-5.19% | 39.88B | |
-5.56% | 28.55B | |
+15.65% | 27.26B | |
-21.22% | 19.23B | |
+33.77% | 12.61B | |
+2.35% | 12.49B | |
+26.64% | 12.28B |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Hansa Biopharma Signs Agreement For Kidney Transplant Treatment Reimbursement In Germany